Insys Therapeutics, Inc. to Present at June Conferences

PHOENIX, May 31, 2017 (GLOBE NEWSWIRE) -- Insys Therapeutics, Inc. ("Insys" or "the Company") INSY today announced that Saeed Motahari, President and Chief Executive Officer, and Darryl Baker, Chief Financial Officer, will present at the following healthcare conferences in June:

The Jefferies presentation will be webcast live at the aforementioned time as well as archived for 90 days thereafter, via the Company's website at www.insysrx.com, under the Investors Section. 

About INSYS
Insys Therapeutics is a specialty pharmaceutical company that develops and commercializes innovative drugs and novel drug delivery systems of therapeutic molecules that improve the quality of life of patients. Using proprietary sublingual spray technology and capabilities to develop pharmaceutical cannabinoids, INSYS is developing a pipeline of products intending to address unmet medical needs and the clinical shortcomings of existing commercial products. INSYS currently markets one product, SUBSYS® (fentanyl sublingual spray), CII, and has received approval for the marketing of SYNDROS™ (dronabinol) oral solution, CII, a proprietary, orally administered liquid formulation of dronabinol that INSYS believes has distinct advantages over the current formulation of dronabinol in soft gel capsule. INSYS is committed to developing medications for potentially treating addiction to opioids, opioid overdose, epilepsy, and other disease areas with a significant unmet need.

SUBSYS® and SYNDROS™ are trademarks of Insys Development Company, Inc., a subsidiary of Insys Therapeutics, Inc.

Contact:
Lisa M. Wilson
T: 212-452-2793
E: INSYS@insysrx.com